Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
69.65
-0.28 (-0.40%)
At close: Oct 29, 2025, 4:00 PM EDT
69.60
-0.05 (-0.07%)
Pre-market: Oct 30, 2025, 4:04 AM EDT
Avidity Biosciences Stock Forecast
Stock Price Forecast
The 19 analysts that cover Avidity Biosciences stock have a consensus rating of "Buy" and an average price target of $69.26, which forecasts a -0.56% decrease in the stock price over the next year. The lowest target is $55 and the highest is $96.
Price Target: $69.26 (-0.56%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Avidity Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 9 | 4 |
| Buy | 6 | 7 | 7 | 8 | 8 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 14 | 14 | 15 | 17 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades $78 → $74 | Strong Buy → Hold | Downgrades | $78 → $74 | +6.25% | Oct 29, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades $75 → $72 | Strong Buy → Hold | Downgrades | $75 → $72 | +3.37% | Oct 28, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $61 → $72 | Buy → Hold | Downgrades | $61 → $72 | +3.37% | Oct 28, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $75 → $72 | Strong Buy → Hold | Downgrades | $75 → $72 | +3.37% | Oct 27, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $65 → $72 | Buy → Hold | Downgrades | $65 → $72 | +3.37% | Oct 27, 2025 |
Financial Forecast
Revenue This Year
9.43M
from 10.90M
Decreased by -13.43%
Revenue Next Year
19.65M
from 9.43M
Increased by 108.26%
EPS This Year
-4.49
from -2.89
EPS Next Year
-4.94
from -4.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.1M | 68.7M | |||
| Avg | 9.4M | 19.6M | |||
| Low | 4.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 29.2% | 628.0% | |||
| Avg | -13.4% | 108.3% | |||
| Low | -55.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.50 | -3.40 | |||
| Avg | -4.49 | -4.94 | |||
| Low | -6.13 | -7.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.